Metabolic reprogramming in PTSD: GLP-1 receptor agonists and cardiometabolic drug repurposing for precision therapeutics
Frontiers in Behavioral Neuroscience · 2026
Abstract e pubblicazione originale
L’abstract è consultabile nella fonte originale. Non viene ripubblicato qui perché non risulta verificata una licenza compatibile.
Leggi nella fonte originale ↗Parole chiave
Posttraumatic Stress Disorder ResearchStress Responses and CortisolMigration, Health and Traumapost-traumatic stress disordermetabolic reprogrammingcardiometabolic comorbiditiesdrug repurposingGLP-1 receptor agonistsinsulin sensitizersstatinshypothalamic-pituitary-adrenal axisglucocorticoid receptor signalingneuroinflammationinsulin resistancemitochondrial dysfunctionobesitytype 2 diabetescardiovascular disease
Come citare questo studio
Iryna Halabitska, Pavlo Petakh, Iryna Ivanivna Kamyshna, Oleh V. Lushchak, Oleksandr Kamyshnyi. (2026). Metabolic reprogramming in PTSD: GLP-1 receptor agonists and cardiometabolic drug repurposing for precision therapeutics. Frontiers in Behavioral Neuroscience. DOI: 10.3389/fnbeh.2026.1957516
Consulta la pubblicazione originale ↗